What Adelax Treats: Main Uses and Benefits

The medication is applied in addressing symptoms related to anxiety and low mood and is considered relevant in contexts marked by increased discomfort or tension. Adelax is applied in addressing symptomatic discomfort in conditions characterized by periods of heightened symptoms, such as depressive neuroses, psychogenic depression, masked depression, and psychosomatic affections where emotional distress complicates physical symptoms.

The medication is generally useful in situations where patients experience a dual burden of emotional distress and a lack of energy. Adelax is applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning, such as apathy and chronic fatigue (asthenia). It provides support that helps ease the symptom load during these emotional episodes, offering supportive relief to individuals coping with mixed affective states. The medication may also assist with managing functional somatic disorders like certain forms of IBS or functional pain.

---

Quick Fact: Relief for Concurrent Emotional and Somatic Symptoms

Symptom Domain	Symptomatic Benefit
Mixed Emotional Distress	Supports general well-being during symptomatic phases and helps ease inner tension.
Asthenia (Low Drive)	Assists in managing apathy and may assist with managing low energy.
Functional Somatic Complaints	Provides supportive relief for physical discomfort linked to emotional tension.

Regulatory References

1. Malta Medicines Authority package leaflet

Official Eligibility Profile

The eligibility for Adelax is strictly governed by regulatory classifications, outlining populations for whom use is permitted, restricted, or contraindicated.

Category	Eligibility Classification
Age Group	Adults are permitted; Children and adolescents under 18 are not recommended due to a lack of efficacy and safety data. Older adults may require a lower initial dose.
Contraindicated Conditions	The medicine is contraindicated for patients with a recent myocardial infarction, certain disorders of cardiac rhythm, untreated narrow-angle glaucoma, and acute alcohol/barbiturate/opiate intoxication.
Concomitant Therapy	Use is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) or within two weeks of stopping an MAOI.
Physiological Status	It is not recommended for use in severe depression requiring hospitalization or in excitable/overactive patients. Advanced cardiovascular or hepatic disease requires caution.
Maternal Status	Use is not recommended during pregnancy and lactation, and should only be administered if the expected benefit clearly outweighs the theoretical risk to the fetus or infant.

This framework defines mandatory prohibitions for patients with certain cardiovascular and neurological disorders, ensuring adherence to labeled restrictions. Use is generally permitted for adults but requires caution and special consideration in the elderly and those with specific comorbidities like epilepsy or hyperthyroidism.

Interactions with other medicines and products

Adelax's interaction profile, as defined in regulatory documents, is primarily driven by pharmacodynamic potentiation and strict restrictions on contraindicated agents.

Category	Official Regulatory Entities / Statements
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Sympathomimetics, Adrenergic Neurone Blockers, Anticholinergic Agents.
Specific interacting medicines (if explicitly listed)	Lithium (due to risk of neurotoxicity), Guanethidine, Reserpine, Clonidine (as Adrenergic Neurone Blockers).

Official Interaction Statements

• Contraindicated Combinations: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the documented risk of a hypertensive crisis or serotonin syndrome. Acute intoxication states involving alcohol, barbiturates, or opiates are also officially contraindicated.
• Timing Separation: A mandatory two-week period of separation is required between the discontinuation of an MAOI and the initiation of treatment with this medicine, as explicitly stated in regulatory labeling.
• Pharmacodynamic Potentiation: The combination may enhance the CNS depressant effect of substances like alcohol and other CNS depressants, requiring consumption to be avoided or limited, and it may also potentiate the effects of anticholinergic agents.
• Antihypertensive Interference: Regulatory documents state that Adelax may counteract the antihypertensive effects of Adrenergic Neurone Blockers, such as guanethidine.
• Cardiovascular Potentiation: The official label notes that Melitracen may potentiate the cardiovascular effects of Sympathomimetics (e.g., adrenaline, noradrenaline).

---

Adelax functions as a competitive antagonist at peripheral muscarinic acetylcholine receptors (mAChRs), primarily targeting the M3 receptor subtype expressed on the surface of smooth muscle cells and glandular tissue.

The compound binds reversibly to the orthosteric site of the M3 mAChR, preventing the endogenous neurotransmitter acetylcholine (ACh) from binding and initiating signal transduction. This blockade inhibits the Gq protein-coupled intracellular cascade, which typically involves the activation of phospholipase C (PLC) and the subsequent generation of inositol trisphosphate ( IP3) and diacylglycerol (DAG).

The resulting intracellular consequence is a reduction in the release of calcium ions ( Ca^2+) from the sarcoplasmic reticulum. This decreased intracellular calcium concentration prevents the activation of myosin light chain kinase (MLCK), which is essential for initiating smooth muscle contraction. The downstream cascade leads to diminished cholinergic drive in smooth muscle, resulting in a state of myorelaxation in targeted tissues. The system-level physiological consequence is an alteration of parasympathetic outflow, modulating contractility in organ systems innervated by cholinergic fibers.

How to Use Adelax

The medicine Adelax is a fixed-dose combination product for oral administration only. It is supplied as a film-coated tablet containing the standardized amounts of Flupentixol (0.5 mg) and Melitracen (10 mg).

---

Standard Administration and Regimen

The tablets are intended to be swallowed whole with water and should not be chewed. Administration may occur with or without food. Due to the product's activating properties, the dosing schedule is typically restricted to the earlier part of the day to avoid potential sleep interference.

For adults, the usual starting regimen is two tablets daily, taken as one tablet in the morning and one tablet at noon. In cases requiring higher initial support, the daily dose may be increased to three tablets, provided the absolute maximum of four tablets per day is not exceeded. Once the need for higher support diminishes, the dose is generally reduced to a maintenance dose of one tablet daily, typically taken in the morning.

---

Use in Specific Populations

Specific administration instructions exist for certain patient groups. For older adults (above 65 years), the starting dose is typically reduced to one tablet per day, taken in the morning. The maximum recommended daily intake for this population is limited to two tablets. Use in children and adolescents under 18 years of age is generally not recommended as the safety and efficacy profile has not been fully established in this group.

Treatment duration is individualized; however, if no clinical improvement is observed after approximately one week at the maximum dose, discontinuation is typically considered.

Research Evidence / Overview of Studies

Summary of Clinical Evaluation

Early-stage research focused on characterizing the biological effects of the compound, which is a combination of flupentixol (a thioxanthene) and melitracen (a tricyclic antidepressant). The studies assessed changes in symptom severity metrics during the trial period for conditions such as anxiety and depression. Research evaluated whether the drug regimen correlated with measurements of the quality of life for individuals experiencing mood disorders.

---

Key Findings from Pre-Clinical and Phase I Trials

Pre-clinical studies examined the drug’s binding affinity and metabolic profile in isolated cells and animal models. Phase I trials reported on the initial safety metrics and pharmacokinetics (how the body handles the drug) in healthy human volunteers. These trials focused on determining the limits of exposure in human volunteers.

---

Phase II and III Assessment Data

• Symptom Score Measurement: Trials utilizing established rating scales were reviewed to assess changes in reported symptom levels over the study period. A key finding from the research was a correlation between drug administration and changes in reported metrics for anxiety and depression.
• Functional Capacity Assessment: Research examined changes in daily functioning, mobility, and physical activity levels following the drug’s use.
• Combination Assessments: One study examined the use of the drug in combination with light exercise. The combination was assessed in terms of its association with sleep quality metrics and its impact on the concurrent use of other medications.

---

Safety and Tolerability Profile

Various studies assessed the effect of this drug, with one trial reporting a measured response in a large majority of participants. Reported safety data from studies characterized the tolerability of the drug among adult participants, though certain populations, such as those with severe kidney issues, were often excluded from these trials. The adverse events most frequently reported in the trials involved symptoms such as headaches and gastrointestinal discomfort.

Key Studies & References

1. Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial
2. Review Article The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis
3. SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) for Deanxit film-coated tablets (Flupentixol/Melitracen)

Common questions about Adelax (FAQ)

Q: Does Adelax interact with common pain relievers like ibuprofen?

A: Regulatory documents advise caution regarding potential interactions involving the Melitracen component of this medicine and certain common pain relievers known as non-steroidal anti-inflammatory drugs (NSAIDs). Official product information indicates that this combination may increase the risk of gastrointestinal bleeding. The complete medication list for an individual is a key consideration for their prescribing healthcare professional.

Q: Can Adelax be used by people with kidney issues?

A: Official documents advise that caution is needed in patients who have pre-existing kidney or liver conditions. Furthermore, individuals with severe kidney issues were often excluded from the original clinical trials used for regulatory review. Use in these populations may require special consideration and assessment by a healthcare professional.

Q: How long does it usually take for Adelax to start working?

A: Official administration instructions provide a timeframe for reassessment, suggesting that if no signs of clinical improvement are observed after approximately one week at the maximum dose, discontinuation should be considered. This reference point is used as a guideline for initial treatment review by healthcare professionals.

Q: How long does the effect of one dose of Adelax typically last?

A: The duration of the effect is related to how the body processes the medicine, which is called pharmacokinetics. The drug contains two active components, each with its own processing time. Official information indicates the biological half-life of Flupentixol is approximately 35 hours, while the half-life of Melitracen is approximately 19 hours.

Q: Can Adelax affect my ability to drive?

A: Regulatory warnings indicate that the ability to operate machinery or drive may be affected by the medicine. This is due to the potential for common side effects such as sleepiness (somnolence) and dizziness that are listed in the official product information.

Q: What is the risk of stopping Adelax suddenly?

A: Regulatory information indicates that treatment is usually withdrawn gradually to help minimize the experience of discontinuation symptoms, rather than stopping the medicine suddenly. This is a common practice for medicines of this type.

Q: How quickly does Adelax leave the body?

A: The speed at which the medicine leaves the body is described by the half-life of its components in pharmacokinetic data. Official product information states that the biological half-life of Flupentixol is approximately 35 hours, and the half-life of Melitracen is approximately 19 hours.

Q: What should I know about Adelax and alcohol consumption?

A: Official documents state that the medicine may enhance the central nervous system (CNS) depressant effects of substances like alcohol. Because of this potential for increased sedation and other effects, regulatory warnings recommend that consumption of alcohol be avoided or limited.

Q: Can Adelax cause drowsiness or fatigue?

A: Official safety data lists sleepiness (somnolence) as a commonly reported effect of the medicine among participants in clinical studies. This finding is one of the recognized neurological effects of the medicine's components.

Q: Is it normal to have mild headaches when starting Adelax?

A: Official safety data characterizes headaches as an adverse event that was frequently reported by participants during clinical trials. This indicates that headaches are a known and common occurrence associated with the medicine's use.

Q: What is the risk of Neuroleptic Malignant Syndrome (NMS) with Adelax?

A: The official labeling notes that Neuroleptic Malignant Syndrome (NMS) is a potential serious adverse reaction associated with the neuroleptic component of the medicine. While serious, this syndrome is reported to occur rarely, consistent with the class of medicine, and is an officially documented safety concern.

Official Storage and Disposal Requirements

The required storage conditions for Adelax (Flupentixol/Melitracen) tablets are explicitly defined in regulatory documentation to ensure product quality and safety.

Item	Official Regulatory Requirement
Storage Temperature	Store at a temperature not exceeding 30 C (86 F) in a dry place.
Handling Requirements	Protect from light and keep in a dry place. Do not refrigerate or freeze.
Packaging Rules	Tablets must be stored in the original container (blister pack or bottle).
Child Safety	Keep out of reach of children.
Disposal	Unused or expired Adelax must be disposed of according to local regulations.
Environmental Rule	Do not dispose of via wastewater or household waste to protect the environment.

These statements require the user to maintain the specified temperature and environmental conditions, prohibit certain storage environments, and mandate that disposal must follow authorized pharmaceutical waste procedures.